Noncanonical Cell Fate Regulation by Bcl-2 Proteins.


Journal

Trends in cell biology
ISSN: 1879-3088
Titre abrégé: Trends Cell Biol
Pays: England
ID NLM: 9200566

Informations de publication

Date de publication:
07 2020
Historique:
received: 17 02 2020
revised: 15 03 2020
accepted: 19 03 2020
pubmed: 21 4 2020
medline: 25 6 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

Bcl-2 proteins are widely known as key controllers of mitochondrial outer membrane permeabilization, arguably the most important step of intrinsic apoptosis. Accumulating evidence indicate that most, if not all, members of the Bcl-2 protein family also mediate a number of apoptosis-unrelated functions. Intriguingly, many of these functions ultimately impinge on cell fate decisions via apoptosis-dependent or -independent mechanisms, delineating a complex network through which Bcl-2 family members regulate cell survival and death. Here, we critically discuss the mechanisms through which Bcl-2 proteins influence cell fate as they regulate autophagy, cellular senescence, inflammation, bioenergetic metabolism, Ca

Identifiants

pubmed: 32307222
pii: S0962-8924(20)30070-2
doi: 10.1016/j.tcb.2020.03.004
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins c-bcl-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

537-555

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Stephen Jun Fei Chong (SJF)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Saverio Marchi (S)

Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.

Giulia Petroni (G)

Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.

Guido Kroemer (G)

Equipe Labellisée par la Ligue Contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-, HP, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou, China; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden; Université de Paris, Paris, France.

Lorenzo Galluzzi (L)

Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Université de Paris, Paris, France; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA. Electronic address: deadoc80@gmail.com.

Shazib Pervaiz (S)

Université de Paris, Paris, France; Department of Physiology, YLL School of Medicine and NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore; National University Cancer Institute, National University Health System, Singapore. Electronic address: phssp@nus.edu.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH